Incyte Presents Positive Phase 1/2 Data for Latarcibart in Von Willebrand Disease, Supporting Ongoing Phase 3 Development Incyte has announced comprehensive safety and efficacy results from its Phase 1/2 multidose clinical study evaluating VGA039 (latarcibart), an investigational monoclonal antibody designed…
Lineage Cell Therapeutics Advances COR1 Program to Develop Off-the-Shelf Cell Therapy for Corneal Endothelial Disease Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf cell therapies for serious medical conditions, has announced significant progress in the…
HistoSonics Secures CE Mark Approval for Edison® Histotripsy System, Expanding Non-Invasive Liver Tumor Treatment Across Europe HistoSonics has achieved a significant regulatory milestone with the receipt of CE Mark approval for its Edison® Histotripsy System, paving the way for commercialization…
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate Bausch + Lomb Corporation a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating…
Evolus Expands Aesthetic Portfolio with Exclusive U.S. Licensing Agreement for Profhilo®, Europe’s Leading Injectable Skin Quality Treatment Evolus, Inc., a global performance beauty company focused on developing innovative consumer aesthetic brands, has announced an exclusive licensing and distribution agreement with…
U of T, McMaster and Genesys Capital Launch Early-Stage Life Sciences Fund A major new venture capital initiative is set to strengthen Ontario’s life sciences ecosystem by providing early-stage funding to promising health technology startups emerging from academic research. The…
Turn Therapeutics Finalizes Phase 2 Study Design for GX-03 Following Positive Interim Analysis in Atopic Dermatitis Turn Therapeutics, Inc., a clinical-stage biotechnology company focused on developing targeted, non-systemic therapies for inflammatory skin disorders, has announced the completion of a comprehensive…
Agenus Reports Landmark Three-Year Phase 1b Data Showing Durable Survival with Botensilimab Plus Balstilimab in Refractory MSS Metastatic Colorectal Cancer Agenus Inc., a biotechnology company focused on advancing next-generation immuno-oncology therapies, has announced encouraging three-year follow-up data from its fully…
Alzheon to Present Nine Scientific Posters at AAIC 2026 Highlighting New Clinical, Imaging, Biomarker, and Long-Term Data for Investigational Alzheimer’s Therapy Valiltramiprosate Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing therapies and diagnostic technologies for Alzheimer’s disease (AD) and…
VIVAZEN Welcomes DEA Scheduling of Synthetic 7-Hydroxymitragynine, Reinforces Commitment to Safe Botanical Wellness and Consumer Transparency VIVAZEN®, a leading botanical wellness company in the United States, has welcomed the recent decision by the U.S. Drug Enforcement Administration (DEA) to classify…
HeartBeam Completes Patient Enrollment Ahead of Schedule in ALIGN-ACS Pilot Study for Heart Attack Detection HeartBeam, Inc., a medical technology company focused on advancing cardiovascular diagnostics through innovative electrocardiogram (ECG) technology, has announced the successful completion of patient enrollment in…
Tenpoint Therapeutics Launches National ‘Friends of the Presbyopians’ Campaign to Raise Awareness of YUVEZZI for Age-Related Near Vision Loss Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company dedicated to developing innovative therapies that improve vision in the aging eye,…